Page 11 - Nasdaq Mrns News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq mrns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Mrns Today - Breaking & Trending Today

Marinus Pharmaceuticals (NASDAQ:MRNS) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) issued its earnings results on Monday. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.76) by ($0.01), MarketWatch Earnings reports. Marinus Pharmaceuticals had a negative return on equity of 86.10% and a negative net margin of 572.12%. During the […] ....

Thomson Reuter , Morgan Stanley , Zacks Investment Research , Marinus Pharmaceuticals Company Profile Get Rating , Invesco Ltd , Marinus Pharmaceuticals , York Mellon Corp , Marinus Pharmaceuticals Inc , Earnings History For Marinus Pharmaceuticals , Dimensional Fund Advisors , Get Rating , Marketwatch Earnings , New York Mellon Corp , Fund Advisors , Pharmaceuticals Company Profile , Nasdaq Mrns ,

Marinus Pharmaceuticals (NASDAQ:MRNS) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) announced its earnings results on Monday. The biopharmaceutical company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.01), MarketWatch Earnings reports. Marinus Pharmaceuticals had a negative net margin of 572.12% and a negative return on equity of 86.10%. During the same […] ....

Morgan Stanley , Geode Capital Management , Marinus Pharmaceuticals Get Rating , Zacks Investment Research , Blackrock Inc , Marinus Pharmaceuticals , York Mellon Corp , Marinus Pharmaceuticals Inc , Earnings History For Marinus Pharmaceuticals , Dimensional Fund Advisors , Get Rating , Marketwatch Earnings , Capital Management , New York Mellon Corp , Fund Advisors , Nasdaq Mrns ,

Marinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.com

StockNews.com lowered shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) from a hold rating to a sell rating in a report issued on Friday morning. Other research analysts have also recently issued research reports about the company. JMP Securities reissued a buy rating and issued a $23.00 price objective on shares of Marinus Pharmaceuticals in […] ....

Sofinnova Investments Inc , Zacks Investment Research , Blackrock Inc , Deutsche Bank , Marinus Pharmaceuticals Company Profile Get Rating , Analyst Recommendations For Marinus Pharmaceuticals , Marinus Pharmaceuticals , Wells Fargo Company , Walleye Capital , Marinus Pharmaceuticals Inc , Get Rating , Investment Research , Sofinnova Investments , Pharmaceuticals Company Profile , Nasdaq Mrns , Stocknews Com ,

Marinus Pharmaceuticals (NASDAQ:MRNS) Price Target Increased to $22.00 by Analysts at JMP Securities

Marinus Pharmaceuticals (NASDAQ:MRNS – Get Rating) had its price objective lifted by investment analysts at JMP Securities from $21.00 to $22.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “market outperform” rating on the biopharmaceutical company’s stock. JMP Securities’ price target suggests a potential upside of 151.72% from the […] ....

Life Insurance Co , Zacks Investment Research , Marinus Pharmaceuticals Company Profile Get Rating , Analyst Recommendations For Marinus Pharmaceuticals , Invesco Ltd , Marinus Pharmaceuticals , Walleye Capital , Marinus Pharmaceuticals Inc , Citigroup Inc , Get Rating , Truist Financial , Pharmaceuticals Company Profile , Nasdaq Mrns , Boost Price Target , Jmp Securities ,